Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function [1]

AIDS

Volumn 20, Issue 18, 2006, Pages 2399-2400

  Manfredi, Roberto ^a   Sabbatani, Sergio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALBUMIN; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMPRENAVIR PHOSPHATE; ANTIHISTAMINIC AGENT; ATAZANAVIR; ATOVAQUONE; BILIRUBIN; CHOLINESTERASE; CORTICOSTEROID; CREATININE; FLUCONAZOLE; GAMMA GLUTAMYLTRANSFERASE; INDINAVIR; LACTATE DEHYDROGENASE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STEROID;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; BILIRUBIN BLOOD LEVEL; BONE MARROW TOXICITY; CASE REPORT; CHOLINESTERASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ESOPHAGUS CANDIDIASIS; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPYREXIA; INTENSIVE CARE; KIDNEY FAILURE; KIDNEY FUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; LEUKOCYTE COUNT; LIVER TOXICITY; MACULOPAPULAR RASH; MYELOPOIESIS; NEPHROTOXICITY; OLIGURIA; PRIORITY JOURNAL; PRURITUS; RASH; SKIN ALLERGY; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG HYPERSENSITIVITY; EXANTHEMA; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; KIDNEY DISEASES; LIVER DISEASES; MYELOPOIESIS; PYRIMIDINONES;

EID: 33751227182     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328010f212     Document Type: Letter

References (9)

1. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at: http://AIDSinfo.nih.gov:1-112. Accessed: September 2006.
2. Sulkowski MS, Metha SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18:2277-2284.
3. Vogel M, Rocksroh JK. Safety of lopinavir/ritonavir for the treatment of HIV-infection. Expert Opin Drug Safety 2005; 4:403-420.
4. Liechty CA, Solberg P, Mwima G, Were W, Weidle PJ, Mermin J. Nevirapine-induced Stevens-Johnson syndrome in a mother and son. AIDS 2005; 19:993-994.
5. Colebunders R, Vanwolleghem T, Meurrens P, Moerman F. Efavirenz-associated Stevens-Johnson syndrome. Infection 2004; 32:306-307.
6. Calista D. Maculo-papular rash induced by lopinavir/ritonavir. Eur J Dermatol 2005; 15:97-98.
7. Ghosn J, Duvivier C, Tubiana R, Katlama C, Caumes E. Acute generalized exanthematous pustolosis induced by HIV postexposure prophylaxis with lopinavir/ritonavir. Clin Infect Dis 2005; 41:1360-1361.
8. Cho ME, Kopp JB. HIV and the kidney: a status report after 20 years. Curr HIV/AIDS Rep 2004; 1:109-115.
9. Szeto CC, Chow KM. Nephrotoxicity related to new therapeutic compounds. Renal Fail 2005; 27:329-333.